BACKGROUND: Recent studies suggested that @entity2690 glargine use could be associated with increased risk of @entity5 . We compared the incidence of @entity5 in new users of glargine versus new users of NPH in a longitudinal clinical cohort with @entity6 for up to 6 years. METHODS AND FINDINGS: From all @entity1 who had been regularly followed at Massachusetts General Hospital from 1/01/2005 to 12/31/2010, 3,680 @entity1 who had a medication record for glargine or NPH usage were obtained from the electronic medical record (EMR). From those we selected 539 new glargine users (age: 60.1  13.6 years, BMI: 32.7  7.5 kg/m2) and 343 new NPH users (61.5  14.1 years, 32.7  8.3 kg/m2) who had no prevalent @entity5 during 19 months prior to glargine or NPH initiation. All incident @entity5 cases were ascertained from the EMR requiring at least 2 ICD-9 codes within a 2 month period. @entity2690 exposure time and cumulative dose were validated. The statistical analysis compared the rates of @entity5 in new glargine vs. new NPH users while on treatment, adjusted for the propensity to receive one or the other @entity2690 . There were 26 and 28 new @entity5 cases in new glargine and new NPH users for 1559 and 1126 @entity1 -years follow-up, respectively. There were no differences in the propensity-adjusted clinical characteristics between groups. The adjusted hazard ratio for the @entity5 incidence comparing glargine vs. NPH use was 0.65 (95% CI: 0.36-1.19). CONCLUSIONS: @entity2690 glargine is not associated with development of @entity5 when compared with NPH in this longitudinal and carefully retrieved EMR data.

Electronic Medical Record Cancer Incidence over Six Years Comparing New Users of Glargine with New Users of NPH XXXX .

@entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'cancer'] @entity1 :: ('9606', 'Species') :: ['patients', 'person'] @entity2690 :: ('3630', 'Gene') :: ['Insulin', 'insulin'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']
@entity2690 :: (3630,Gene) :: ['Insulin']
